LIVE INFLUENZA VACCINE FOR CHILDREN AND ADULTS: TRANSMISSIBILITY IN CHILDREN 3-6 YEARS OF AGE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences, St. Petersburg Live attenuated influenza vaccines (LAIV) are used in Russia to immunize all population groups, including children. The immunogenicity, acceptance, and transmissibility of the components of commercially available trivalent LAIV vaccine in vaccinated children aged 3 to 6 years were studied. Vaccine viruses were isolated from nasal swabs of the vaccinees, using chicken embryos and MDCK cells. The use of a combination of these two culture systems produced the best effect in isolating vaccine viruses. Examination of placebo group children who were in constant contact with the vaccinated subjects showed that LAIV strains had not been transmitted from the vaccinated to unvaccinated children. The acceptance of vaccine virus correlated well with its immunogenicity.

Full Text

Restricted Access

About the authors

N. V LARIONOVA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

Email: nvlarionova@mail.ru
St. Petersburg

I. V KISELEVA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

St. Petersburg

E. P GRIGORIEVA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

St. Petersburg

I. N ISAKOVA-SIVAK

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

St. Petersburg

S. A DONINA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

St. Petersburg

L. G RUDENKO

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

St. Petersburg

References

  1. Александрова Г.И., Климов А.И. Живая вакцина против гриппа. СПб: Наука, 1994.
  2. Klimov A.I., Kiseleva I.V., Desheva J.A. et al. Live attenuated reassortant influenza vaccine prepared usingA/Leningrad/134/17/57 (H2N2) donor strain is genetically stable after replication in children 3-6 years of age In: Proceedings of options for the control of influenza IV. Hersonissos, Crete, Greece. 23-28 September 2000. Amsterdam: Elsever Sciense, 2001: 951-954.
  3. van Voorthuizen F., Jens D., Saes F. Characterization and clinical evaluation of live influenza A vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold adapted A/Ann Arbor/6/60 (H2N2) strains. Antivir. Res. 1981; 1: 107-122.
  4. Vesikari T., Karvonen A., Korhonen T. et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Ped. Inf. Dis. J. 2006; 25 (7): 590-595.
  5. Иванова В.Т., Бурцева Е.И., Слепушкин А.Н. и др. Характеристика штаммов вируса гриппа А(Н3N2) в эпидемическом сезоне 2003-2004 гг. в России. Вопр. вирусол. 2006; 1: 19-23.
  6. Litvinova O., Konovalova N., Lobova T. The etiological surveillance for influenza in Russia during the seasons 1993— 2003. International Congress Series 1263. 2004: 295-298.
  7. Демидова С.А., Гадашевич В.Н., Кириллова Ф.М. и др. Выделение и изучение вирусов гриппа А на разных клеточных культурах. Вопр. вирусол. 1979; 4: 346-350.
  8. Davies H.W., Appleyard G., Cunningham P. et al. The use of a continuous cell line for the isolation of influenza viruses. Bull. WHO 1978; 56: 991-993.
  9. Инструкция по применению вакцины гриппозной аллантоисной интраназальной живой сухой. Утверждена Главным санитарным врачом РФ Г.Г. Онищенко 16 июня 2004 г.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies